Inovio responds to Mr. Feuerstein's article

|About: Inovio Pharmaceuticals... (INO)|By:, SA News Editor

Pertaining to efficacy, the study measures regression of disease from late-stage cervical pre-cancer (CIN 2/3) to early stage pre-cancer (CIN 1) or elimination of disease. The study is 80% powered to achieve a 52% response rate in vaccinated subjects compared to a hypothetical 25% in the control group. The 25% figure is based on natural regression response rates that have ranged from 4% - 40% in other studies.

CEO Joseph Kim will undoubtedly join Northwest Biotherapeutics (NWBO +5.8%) Chief Linda Powers in declining a dinner invitation with Mr. Feuerstein.